NCT07842926 Acute Effects of Capacitive-Resistive Radiofrequency Therapy in People With Parkinson's Disease
| NCT ID | NCT07842926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad San Jorge |
| Condition | Parkinson Disease (PD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-09-21 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-09-21 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate the immediate and short-term effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs in people with Parkinson's disease. The main aim is to determine which of four different TECAR application protocols produces the greatest improvement in muscle stiffness and walking function. Twenty participants with Parkinson's disease will receive four different TECAR protocols in four separate sessions. The protocols will include capacitive treatment, resistive treatment, and two combinations of capacitive and resistive treatment. Each participant will receive all four protocols, and the order in which they are applied will be randomized. Sessions will be separated by a 7-day washout period. Muscle stiffness will be measured using the MyotonPRO device. Walking and functional mobility will also be assessed using the Timed Up and Go test and the 10-Metre Walk Test. Joint range of motion and lower-limb musculoskeletal pain will also be evaluated. Measurements will be performed immediately before treatment, immediately after treatment, and 48 hours after each session. The study will also record any discomfort or adverse events associated with TECAR therapy to evaluate the safety and tolerability of the different treatment protocols.
Eligibility Criteria
Inclusion Criteria: * Age between 55 and 90 years. Clinical diagnosis of idiopathic Parkinson's disease confirmed by a Neurology specialist. Hoehn and Yahr stage II or III. Functional walking ability. Clinically relevant lower-limb rigidity in at least one leg, defined as a score ≥2 on item 3.3d (right lower limb) or 3.3e (left lower limb) of Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Stable antiparkinsonian pharmacological treatment during the previous 4 weeks, with no planned changes during the intervention period. Ability to understand and follow simple instructions, defined as a score \>24 on the validated Spanish version of the Mini-Mental State Examination (MMSE-MEC). Provision of written informed consent. Exclusion Criteria: * Advanced Parkinson's disease, defined as Hoehn and Yahr stage \>III, with severe postural instability. Other neurological or musculoskeletal conditions that could interfere with the assessment of lower-limb rigidity or gait. Skin lesions, open wounds, or infection in the area where radiofrequency therapy will be applied. Presence of a pacemaker, defibrillator, other implanted electronic device, or another contraindication to TECAR therapy, such as altered thermal sensitivity. Lower-limb surgery within the previous 6 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07842926 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 90 Years, studying Parkinson Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07842926 currently recruiting?
Yes, NCT07842926 is actively recruiting participants. Contact the research team at pcordova@usj.es for enrollment information.
Where is the NCT07842926 trial being conducted?
This trial is being conducted at Zaragoza, Spain.
Who is sponsoring the NCT07842926 clinical trial?
NCT07842926 is sponsored by Universidad San Jorge. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.